Watchful monitoring for hepatitis B reactivation after intensive chemotherapy.
Chalandon
Y
Y
Negro
F
F
Hebert
D
D
Dietrich
P Y
PY
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006510:Hepatitis B Antibodies / Q000097:blood*; D019694:Hepatitis B, Chronic / Q000175:diagnosis* / Q000209:etiology; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D018570:Risk Assessment; D012698:Serologic Tests; D013736:Testicular Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy
D000970:Antineoplastic Agents; D006510:Hepatitis B Antibodies